MedPacto, Inc. (235980.KQ) KOE

5,610.00

+30(+0.54%)

Updated at January 22 09:44AM

Currency In KRW

MedPacto, Inc.

Address

Borim Building

Seoul, 06668

Korea, Republic of

Phone

82 2 6938 0200

Sector

Healthcare

Industry

Biotechnology

Employees

56

First IPO Date

December 19, 2019

Key Executives

NameTitlePayYear Born
Seong-Jin KimFounder & Chief Executive Officer0N/A
Jungwon WooPresident0N/A
Timothy R. AllenExecutive Vice President of Clinical Development at MedPacto Therapeutics - U.S.0N/A
Ki Baik HahmExecutive Vice President of R&D0N/A
Sunjin HwangChief Medical Officer0N/A

Description

MedPacto, Inc., a drug discovery and development company, develops and delivers therapeutics targeting cancer and autoimmune diseases in South Korea. The company is developing ME-1601mAb that targets BSP1 for cancers; MS-1601A that targets TRG1 for cancers and autoimmune diseases; and vactosertib for solid tumors. MedPacto, Inc. is based in Seoul, South Korea.